- Role
- Country
- Date of registration
- Address
EUDAMED last updated this device on Jun 8, 2026
B-03532672000059i-Tracker Anti-Ustekinumab is an IVDD-legacy in vitro diagnostic registered in EUDAMED. It is classified as IVDD — General. Manufactured by BIOSYNEX. Placed on the EU market in France. Explore certificates, regulatory status and the EUDAMED record on MD Atlas.
03532672000059CTU 003-50(01)03532672000059
European Medical Device Nomenclature — the EU product classification assigned to this device.
W0102080799AUTOIMMUNE DISEASE TDM - OTHER1 warning recorded — scroll inside the panel to see all entries.
CW010Primary placement in France; available across 1 country total.
| Country | On market since | Until |
|---|---|---|
| FrancePrimary placement | — | Still on market |
FR-MF-000042615Sterile
A sterile device is supplied free of viable micro-organisms — flagged so that it is handled, stored and used to preserve that sterile state.
View in glossary →Single-use device
A single-use device is intended to be used on one patient during a single procedure and then discarded — not reprocessed or reused.
View in glossary →Primary DI
The Primary DI is the main UDI-DI a manufacturer designates as the principal identifier for a device in EUDAMED.
View in glossary →Basic UDI-DI
The Basic UDI-DI is the main identifier that groups together all device variants of the same model — the regulatory "family" key.
View in glossary →UDI issuing entities
Issuing entities are the organisations the European Commission has designated to assign Unique Device Identifiers under the EU's UDI system.
View in glossary →IVDR risk classes
IVDR risk classes rank in-vitro diagnostic devices from lowest risk (Class A) to highest (Class D), based on the patient and public-health risk of a wrong result.
View in glossary →Primary DI
The Primary DI is the main UDI-DI a manufacturer designates as the principal identifier for a device in EUDAMED.
View in glossary →No certificate specifically references this device's Basic UDI-DI.
353267CTO003AVAOn the marketi-Tracker Anti-Risankizumab353267CTRZ003A95On the marketi-Tracker Anti-RituximabB-03532672000158On the marketi-Tracker Anti-VedolizumabB-03532672000073On the marketi-Tracker CertolizumabB-03532672000080On the marketi-Tracker Etanercept353267CTE002ARROn the marketNo certificates registered for this manufacturer.
No certificate references this Basic UDI-DI, because: • It does not require a certificate, or • It only requires a certificate without a Basic UDI-DI reference (e.g. a QMS certificate), or • The required certificate(s) referencing this Basic UDI-DI have not been registered yet.